The development and widespread use of intravitreal endothelial growth factor (VEGF) inhibitors has transformed the management of neovascular age-related macular degeneration (AMD), reducing the number of cases of legal blindness by 50% over the last decade [1,2]. The gene discussed is VEGFA; the disease is age-related macular degeneration.